Role of Genetic Testing in Myelodysplastic Syndromes
Published Online: Tuesday, March 25, 2014
For High-Definition, ClickGenetic analyses are beginning to play a larger role in the diagnosis and determination of prognosis for patients with myelodysplastic syndrome (MDS). However, these assays should still be viewed alongside traditional blood and bone marrow test results, since genetic similarities exist between MDS, acute myeloid leukemia (AML), and certain lymphomas, notes Rafael Bejar, MD, PhD.
Certain cytogenetic abnormalities are associated with MDS by World Health Organization classification, such as 5q deletions. Moreover, Bejar notes, certain splicing factor mutations, such as those in SRSF2, SF3B1, and U2AF1, are more enriched in patients with MDS than those with AML and chronic myeloid leukemia (CML). For patients with an uncertain diagnosis, genetic testing can be utilized as a confirmation. Moreover, in patients with a confirmed diagnosis of MDS, specific mutations could help determine prognosis and the aggressiveness of therapy.
At this point, the predictive value of these genetic signatures is best utilized in low-risk patients, believes Rami S. Komrokji, MD, since the integration of molecular data results in the upstaging of approximately 20% to 30% of patients with low-risk MDS. This upstaging is particularly true when using the International Prognostic Scoring System, notes Bejar. The addition of markers such as ferritin, LDH, and mutations can result in a diagnosis of more advanced disease, especially within the intermediate category.
In terms of treatment, these genetic mutations should be viewed with reservation until further clinical data is available, warns Bejar. In some situations, the mutations that predict more aggressive disease may also predict resistance to therapy, suggesting that earlier treatment may not necessarily lead to better outcomes, Bejar states.
View More From This Discussion
Mark J. Levis, MD, PhDDirector, Adult Leukemia Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Elias J. Jabbour, MDAssociate Professor,
Department of Leukemia,
Division of Cancer Medicine,
MD Anderson Cancer Center, Houston, Texas
Rami S. Komrokji, MDClinical Director, Associate Member, Department of Malignant Hematology
H Lee Moffitt Cancer Center
Ruben A. Mesa, MDChair, Division of Hematology
& Medical Oncology, Mayo Clinic, Scottsdale, Arizona
Rafael Bejar, MD, PhDAssistant Professor of Medicine, Division of Hematology-Oncology
University of California, San Diego, La Jolla, California
Online CME Activities
Most Popular Right Now
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.